Abstract
The caudate and putamen have the same structure (Table 12.1) and are continuous anteriorly. The globus pallidus has two sectors: a medial or inner and a lateral or outer. The substantia nigra has two components: a ventral pars reticularis which is identical in structure and function to the medial sector of the globus pallidus and a dorsal darkly staining component the pars compacta which contains large dopamine and melanin containing neurons. The nuclei of the basal ganglia may be categorized as (1) input nuclei (caudate, putamen, and accumbens), (2) intrinsic nuclei (lateral segment of the globus pallidus, subthalamic nucleus, pars compacta of the substantia nigra, and the ventral tegmental area) and (3) output nuclei (medial segment of the globus pallidus, pars reticularis of the substantia nigra, and the ventral pallium). The consideration of the chemical and pharmacological anatomy of transmitters and circuits within the system will provide an understanding of function and dysfunction within this system.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cooper, J. R., Bloom, F. E., and Roth, R. H. 1991.The Biochemical Basis of Neuropharmacology. New York. Oxford University Press. (See in particular Chapter 10: Dopamine pp.285–337).
Riley, D. E. and A. E. Lang. 2000. Movement disorders. (in) Bradley, W. G., R. B. Daroff, G. M. Fenichel and C. D. Marsden. Neurology in Clinical Practice. Boston, Butterworth Heinemann. II: 1889–1930.
Albin, R. I., Young,A. B., Penney,J.B., et al. 1990. Abnormalities of Striatal Projection Neurons And N-Methyl D-Aspartate Receptors in Presymptomatic Huntington’s Disease. N. Engl. J. Med.322:1293–1298.
Aziz.T.Z., Peggs.D., Sambrook.M.A., and Crossman.A.R. 1991. Lesion Of the Subthalamic Nucleus for the Alleviation of l-Methyl-4 Phenyl 1,2,3,6, Tetrahydropyridine (MPTP) Induced Parkinsonism In the Primate. Movement Disorders. 6:288–292.
Ballard, P.H., Tetrud, J.W., and Langston, J.W. 1985.Permanent Human parkinsonism due to l-methyl-4 phenyl, 1,2,3,6, tetra-Hydropyrine (mptp): seven cases. Neurology, 35:949–56.
Bergman, H., Wichmann, T., DeLong, M.R. 1990. Reversal of Experimental Parkinsonism by Lesions of the Subthalamic Nucleus. Science. 249:1436–1438.
Cote, L., and Crutcher, M.D. 1991.The Basal Ganglia (in) Kandel, E.R., Schwartz, J.H., Jessell, T.M.: Principles of Neural Science 3rd Ed.. N.Y. Elsevier, pp.647–659.
Cotzias, G.C., Papavasiliou, P.S., and Gellen. R. 1969.Modification of Parkinsonism – Chronic Treatment with L-Dopa. N. Engl. J. Med. 280:337–345.
Cotzias, G. C., M. H. Van Woert and L. M. Schiffer. 1967.Aromatic amino acids and modification of Parkinsonism. N. Engl. J. Med. 276: 374–379.
Dunnett, S. B. and A. Bjorklund. 1999. Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature. 399 supplement Neurological Disorders. A32–A39.
Duvoisin, R. C.1998. Familial Parkinson’s disease.NeuroScience News. 1: 43–46.
Gibb, W.R.G. 1988. The Neuropathology of Parkinsonian Disorders (in) Jankovic, J., and Tolosa,E.: Parkinson’s Disease and Movement Disorders. Baltimore/Munich Urban & Schwarzenberg. pp.205–223.
Goetz, C.G. 1986.Charcot on Parkinson’s Disease. Movement Disorders, 1:27–32.
Graybiel, A.M., Ragsdale, C.W. 1978.Histochemically Distinct Compartments in Stratum of Human, Monkey and Cat Demonstrated by Acetylthiocholinesterase Staining. Proc. Natl. Acad. Sci. USA. 75:5723–26.
Guttman, M. 1992. Dopamine receptors in Parkinson’s disease. Neurologic Clinics. 10:377–386.
Hornykiewicz, O.D. 1970. Physiological, Biochemical and Pathological Backgrounds of Levo Dopa and Possibilities for the Future.Neurology 1.20:(Part 2), 1–13.
Jankovic, J. Parkinsonism plus syndromes. 1989. Movement Disorders 4 (Suppl.1) (S) 95–119.
Kopin, I. J. 1988. MPTP toxicity: Implications for research in Parkinson’s disease. Ann. Rev. Neurosci. 11:81–96.
Lang, A. E. and A. M. Lozano.1998. Medical progress: Parkinson’s disease. N. Eng.J. Med. 339:1044 –1053, 1130–1143.
Langston, J. W., Ballard, P., Tetrud, J.W. and Irwin I. 1983. Chronic Parkinsonism in Humans due to a Product of Meperidine – Analog Synthesis. Science. 219:979–980.
Langston, J.W., Widner, H., Goetz, C.G., et al. 1992.Case Assessment Program for Intracerebral Transplantation (CAPIT). Movement Disorders. 7:2–13.
Laplane, D., M. Levasseur, B. Pillone, et al. 1989. Obsessive compulsive and other behavioral changes with bilateral basal ganglia lesions. Brain. 112:699–725.
Lees, A. J., and Tolosa, E. 1988.Tics (in) Jankovic,J., and Tolosa, E.(Ed): Parkinson’s Disease and Movement Disorders. Baltimore/Munich, Urban and Schwarzenberg, pp.275–281.
Martin, J.B. and Gusella, J.F. 1986.Huntington’s Disease: Pathogenesis and Management. N. Engl. J. Med 315:1267–1276.
Mayeux, R. Y. Stern and S. Spanton. 1985. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 35: 453–461.
Mena, I., Court, J., Fuenzalida, S., et al. 1970.Chronic Manganese’s Poisoning: Treatment with L-Dopa or 5-OH Tryptophane. N. Engl. J. Med. 282:5–10.
Olanow, C. W. and W. G. Tatton. 1999. Etiology and pathogenesis of Parkinson’s disease. Annual Review of Neuroscience. 22: 123–144.
Patten, B.M. 1988. Wilson’s Disease (in) Parkinson’s Disease and Movement Disorders. (Ed) Jankovic,J., and Tolosa,E.: Baltimore/Munich, Urban & Schwarzenberg, 179–190.
Penney, J. B.,Jr and A.B.Young. 1988. Huntington’s disease (in) Jankovic, J. and E. Tolosa. Parkinson’s Disease. Baltimore. Urban and Schwarzenberg. 167–178.
Roberts, L. 1990. Huntington’s gene: So near and so far. Science 247:624–617.
Sax. D. S., and Vonsattel, J. P. 1992.Chorea and Progressive Dementia in an 88-year-old Woman. N. EngI. J. Med.,326:117–124.
Schmidt, W. R. and L. W. Jarcho. 1966. Persistent dyskinesias following phenothiazide therapy. Arch Neurol. 14: 369–377.
Sethi, K. P. 2001. Movement disorders induced by dopamine blocking agents. Seminars In Neurology. 21: 59–68.
Siemers, E. and V. Reddy. 1991. Profile of patients enrolled an a new movement disorders clinic. 6: 336–341.
Suggested Headings
Alexander, G.E., M. R. DeLong and D.L. Strick. 1986. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann. Rev. Neurosci. 9: 357–81.
Bhatia, K. P., R. C. Griggs and L. J. Ptacek. 2000. Episodic movement disorders as channelopathies. Movement Disorders 15: 429–423.
Brashear, A. 2001. The botulinum toxins in the treatment of cervical dystonia. Seminars in Neurology. 21: 85–90.
Brooks, D.J. 1991. Detection of Preclinical Parkinson’s Disease with PET. Neurology. 41: (Suppi.2): 24–27.
Cooper, I.S. 1969. Involuntary Movement Disorders. New York, Paul B. Hoeber.
Crossman, A.R. 1990. A Hypothesis on the Pathophysiological Mechanisms That Underlie Levodopa or Dopamine Agonist Induced Dyskinesia in Parkinson’s Disease: Implications for the Future Strategies in Treatment. Movement Disorders. 5: 100–108.
Crossman, A. R., I. J. Mitchell, M. A. Sambrook and A. Jackson. 1988. Chorea and myoclonus in the monkey induced by Gamma amino butyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanism of chorea. Brain. 121: 1–33.
Daniel, S. E., V. M. de Bruin, and A. J. Lees. 1995. The clinical and pathological spectrum of Steele-Richardson Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain. 118: 759–770.
De Bie, R. M. A., P. R. Schuurman, P. S. de Haan, et al. 1999. Unilateral pallidotomy in advanced Parkinson’s disease: A retrospective study of 26 patients. Movement Disorders. 14: 951–957
Delwaide, P.J., and Gance, M. 1988. Pathophysiology of Parkinson’s Signs (in) Jankovic, J., and Tolosa, E.(Ed) Parkinson’s Disease and Movement Disorders Baltimore/Munich, Urban and Schwarzenberg, 59–73.
Deuschl, G. 2000. Treatment options for tremor. N. Engl. J. Med. 342:505–507.
Ebersbach, G. M. Sojer, F. Valladeoriopla, et al. 1999. Comparative analysis of gait in Parkinson’s disease. Cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain. 122: 1349–1355.
Eidelberg, D., A. Sortel, C. Joachim, et al. 1987. Adult onset Lallervorden- Spatz disease with Neurofibrillary pathology. A discrete clinicalpathological entity. Brain. 110: 993–1013.
Fearnley, J. M. and A. J. Lees. 1990. Striatatonigral degeneration. A clinicopathological study. Brain. 113: 18231824.
Forno, L.S., and E. C. Alford. 1987. Pathology of Parkinson’s Disease (in) Roller,W.C. (Ed.): Handbook of Parkinson’s Disease. N.Y., Marcel-Dekker, pp. 209–236.
Freed, C. R., P. E. Greene, R. E. Breeze, et al. 2001. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. Engl. J. Med. 344: 710–19. (see also editorial by Fischbach, G. D. and G. M. Mc Khann. 2001.Cell therapy for Parkinson’s disease. Engl. J. Med. 344 763–765).
Furukawa, Y. and S. J. Kish. 1999. Dopa responsive dystonia: Recent advances and remaining issues to be addressed. Movement disorders. 14: 709–715.
Gerfan, C. R. and T. M. Engbar. 1992. Molecular neuroanatomic mechanisms of Parkinson’s disease. Neurologic Clinics. 10: 435–449.
Gibb, W.R., P. J. Luthert and C. D. Marsden. 1989. Corticobasal degeneration.Brain 112:1171–1192.
Goerdert, M., R. Jakes and M. G. Spillantini. 1998. Alpha-Synuclein and the Lewy body. Neuroscience News. 1: 47–51.
Goldblatt. D., W. Markesbery and A. G. Reeves. 1974. Recurrent Hemichorea Following Striatal Lesions. Arch. Neurol. 31: 51–54.
Growdon. J. H., M. J. Hirsh, R. J. Wurtman and W. Wiener. 1977. Oral Choline Administration to Patients with Tardive Dyskinesia. N. Engl. J. Med. 297: 524–527.
Guridi, J. and J. A. Obesco. 2001. The subthalamic nucleus, hemiballismus and Parkinson’s disease: Reappraisal of a neurosurgical dogma. Brain. 124: 5–19.
Gusella, J. F., N. S. Wexler, D. M. Conneally, et al. 1983. A polymorphic DNA marker genetically linked To Huntington’s disease. Nature. 306: 234–238.
Guttman, M. 1992. Dopamine receptors in Parkinson’s disease. Neurologic Clinics. 10: 377–386.
Hallett M., I. Litvan, et al. 2000. Scientific position paper of the Movement Disorder Society Evaluation of Surgery for Parkinson’s Disease. 15: 436–438.
Hornykiewicz, O., Kish. S., Beckler. L. E, et al. 1986. Brain Neurotransmitters in Dystonia Musculorum Deformans. N. Engl. J. Med. 315: 347–531.
Huntington, G. 1872. On Chorea. Med. Surg. Report. 26: 317–21.
Huw, R. M., A. J. Lees and N. W. Wood. 1999. Neurofibrillary tangles Parkinsonian disorders-Tau pathology and Taugenetics. Movement Disorders. 14: 731–736.
Jankovic, J. Parkinsonism plus syndromes. 1989. Movement Disorders 4 (Suppl.1) (S) 95–119.
Jancovic, J. 2001. Tourette’s Syndrome. N. Engl. J. Med. 345: 1184–1192.
Jankovic, J., and S. Fahn. 1986. The Phenomenology of Tics. Movement Disorders. 1:17–26.
Jankovic, J., and S. Fahn. 1988. Dystonic syndromes (in) Jankovic, J., and Tolosa, E. (Ed.): Parkinson’s Disease and Movement Disorders. Baltimore/Munich, Urban & Schwarzenberg, pp. 283–314.
Jarman, P. R., M. B. Davis, S. V. Hodgson, et al. 1997. Paroxysmal dystonic choreoathetosis: genetic linkage studies in a British family. Brain. 120: 2125–2130.
Jarman, P. R., K. P. Bhatia, C. Davie, et al. 2000. Paroxysmal dystonic choreoathetosis: Clinical features And investigation of pathophysiology in a large family. Movement Disorders. 15: 648–657.
Kandel, E.: Disorders of Thought: Schizophrenia (in) Kandel, E R., Schwartz, J.H., and Jessell, T.M. 1991. Principles of Neural Science 3rd Ed. N.Y., Elsevier. pp. 853–868.
Keenen, R. E. 1970. The Eaton Collaborative Study of Levo Dopa Therapy in Parkinsonism. Neurology. 20(Part2): 46–59.
Kertesz, A. Corticobasal degeneration. 2000. J. Neurol. Neurosurg. Psychiatry. 68: 275–276.
Kertesz, A., P. Martinez-Lage, W. Davidson and D. G. Munoz. 2000.The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology. 55: 1368–1375.
Klawans, H. L., H. Moses, D. A. Nausieda, et al. 1976. Treatment and Prognosis of Hemiballismus. N. Engl. J. Med. 295: 1348–1350.
Klawans, H. L., G. W. Paulson, S. P. Ringel and A. Barbeau. 1972. Use of L-Dopa in the Detection of Presymptomatic Huntington’s Chorea. N. Engl. J. Med. 286: 1332–4.
Klawans, H. L. 1988. The Pathophysiology of Drug-Induced Movement Disorders (in) Jankovic, J., and Tolosa, E. (Ed.): Parkinson’s Disease and Movement Disorders. Baltimore/Munich, Urban and Schwarzenberg. pp. 315–326.
Koller, W.C. (Ed). 1992. Role of the Controlled Release Formulation of Carbidopa-Levodopa in the Treatment of Parkinson’s Disease. Neurology. 42: (Suppl 1) S-l-60.
Koller, W.C.: Initiating Treatment of Parkinson’s Disease.Neurology. 42:(Suppl 1), 29–32, 1992.
Lamousin, P., P. Krack, P. Pollak, et al. 1998. Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med. 339: 1105–1111.
Lang, A.E., A. M. Lozano, M. E. Duff., et al 1997. Posteroventral medial pallidotomy in advanced Parkinson’s disease. N. Engl. J. Med. 337: 1036–1042.
Langston, J. W. and P. Ballard. 1984. Parkinsonism induced by 1-methyl, 4-phenyl-1,2,3,6, tetrahydropyridine(MPTP): Implications for treatment and pathogenesis of Parkinson’s disease. Can. J. Neurol. Sci. 11: 160–165.
Lees, A. J. 1987. The Steele-Richardson, Olszewski Syndrome (Progressive Supranuclear Palsy) (in) Marsden, CD., and Fahn. S. (Ed.). Movement Disorders 2. London/Boston, Butterworths. Pp 272–287.
Lewin, R. 1983. Trail of Ironies to Parkinson’s Disease. Science. 224: 1083–1085.
Lewin. R. 1984. Brain Enzyme is the Target of Drug Toxin. Science. 225: 1460–1462.
Le Witt. D. A. 1992. Clinical Studies with and Pharmacokinetic Considerations of Sustained Release Levodopa. Neurology. 42: (Suppl 1). 29–31.
Lieberman. A. 1992. Emerging Perspectives in Parkinson’s Disease. Neurology. 42: (Suppl 4): 5–7.
Lindvall, O. 1999. Cerebral implantation in movement disorders: state of the art. Movement Disorders. 14: 201–205.
Lindvall. O., P. Brundin, H. Widner., et al. 1990. Grafts of Fetal Dopamine Neurons Survive and Improve Motor Function in Parkinson’s Disease. Science. 247: 514–577.
Litwin, I. 2001. Diagnosis and management of progressive supranuclear palsy. Seminars in Neurology. 21: 41– 48.
Litwin, I., G. Campbell, C. A. Mangone, et al. 1997. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain. 120.
Marsden, C. D. and S. Fahn. Movement Disorders 2. London/Boston. Butterworths. Pp 166–230.
Mathuranath. P. S., J. H. Xuereb, T. Bak and J. R. Hodges. 2000. Corticobasal degeneration and/or frontal temporal dementia? A report of two overlap cases and review of the literature. J. Neurol. Neurosurg. Psychiatry. 68: 304–312.
Testing for Huntington’s Disease with use of a Linked DNA Marker. N. Engl. J. Med. 318: 535–42.
Martin, J. R. 1951. Hemichorea (hemiballismus) without lesions in the corpus Luysii. Brain. 80: 1–10.
Meyers, R., D.B. Sweeney and J. T. Swidde. 1947. Hemiballismus: Etiology and surgical treatment. J. Neurol. Neurosurg. Psychiatry. 58: 672–692.
Mitchell, I. J., A. Jackson, M. A. Sambrook and A. R. Crossman. 1989. The Role of the Subthalamic Nucleus in Experimental Chorea. Evidence from 2-Desoxyglucose Metabolic Mapping and Horse Radish Peroxidase Tracing Studies. Brain. 112:1533–1548.
Montastruc, J. L., O. Rascol and J. M. Senard. 1999. Treatment of Parkinson’s disease should begin With a dopamine agonist. Movement Disorders. 14: 725–730.
Myers, R. H., D. S. Sax, W. J. Koroshetz, et al. 1991. Factors Associated with Slow Progression in Huntington’s Disease. Arch. Neurol. 48: 800–804.
Myers, R. H., J. P. Vonsattel, T. J. Stevens, et al. 1988. Pathologic assessment of severity in Huntington’s disease. Neurology. 38: 341–347.
Papp, M. I. and P. L. Lantos. 1994. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain. 117: 235–243.
Parkinson, J. 1817. An Essay on the Shaking Palsy. London, Sherwood, Neely & Jones. Reprinted – The Classics of Neurology Neurosurgery Library, Birmingham, Gryphen Editions, 1986.
Pauls, D. L., and J. F. Leckman. 1986. The Inheritance of Gilles de La Tourette’s Syndrome and Associated Behaviors: Evidence for Autosomal Dominant Transmission. N. Engl. J. Med. 315: 993–997.
Pearce, R. K. B. 1999. L- Dopa and dyskinesias in normal monkeys. Movement Disorders.14: Supplement 1: 9–12.
Rinne, J. O., M. S. Lee, P.D. Thompson and C. D. Marsden. 1994. Corticobasal degeneration. A clinical study of 36 cases. Brain. 117: 1183–1196.
Sarma, K., J. M. Waltz, M. Riklan., M. Kosolw and J. S. Cooper. 1970. Relief of Intention Tremor by Thalamic Surgery. J. Neurol.Neurosurg. Psychiat. 33: 7–15.
Schneider. J. S., A. Pope, K. Simpson., et al. 1992. Recovery from Experimental Parkinsonism in Primates with GM1 Ganglioside Treatment. Science. 256: 843–6.
Scheinberg. I.H. and I. Steinlieb. 1984. Wilson’s Disease. Philadelphia. W. B. Saunders.
Schuurman, P.R., D. A. Bosch, P.M.M. Bossuyt, et al. 2000. A comparison of continuous Thalamic stimulation and thalamotomy for suppression of severe tremor. N. Engl. J. Med. 342: 461–468.
Schwarz, G. A. and L. J. Barrows. 1960. Hemiballism without involvement of Luy’s body. Arch Neurol. 2: 420–434.
Singer, H. S. 2000. Current issues in Tourette’s syndrome. Movement Disorders. 15: 1051–1063.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jacobson, S., Marcus, E.M. (2011). Motor System II: Basal Ganglia. In: Neuroanatomy for the Neuroscientist. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9653-4_12
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9653-4_12
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-9652-7
Online ISBN: 978-1-4419-9653-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)